Vimarsana
Biggest News Aggregation in the World

Ichnos Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ichnos Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ichnos Sciences Today - Breaking & Trending Today

Glenmark and Ichnos take a collaborative leap to accelerate innovation in Cancer Treatment with their alliance - 'Ichnos Glenmark Innovation' - Vimarsana News

Glenmark and Ichnos take a collaborative leap to accelerate innovation in Cancer Treatment with their alliance - 'Ichnos Glenmark Innovation'

(This story has not been edited by THE WEEK and is auto-generated from a PTI

Source: theweek.in
Glenmark and Ichnos take a collaborative leap to accelerate innovation in Cancer Treatment - Vimarsana News

Glenmark and Ichnos take a collaborative leap to accelerate innovation in Cancer Treatment

Glenmark Pharmaceuticals Ltd , a leading, research-driven, global pharmaceutical company, and Ichnos Sciences...

Glenmark Pharmaceuticals and Ichnos Sciences establish alliance for cancer drug discovery - Vimarsana News

Glenmark Pharmaceuticals and Ichnos Sciences establish alliance for cancer drug discovery

IGI is introducing a pipeline of three oncology molecules currently undergoing clinical trials, targeting multiple myeloma, acute myeloid leukemia, and solid tumors.

Stocks in news: Infosys, RITES, Paytm, Persistent Systems, IRCON and more - Vimarsana News

Stocks in news: Infosys, RITES, Paytm, Persistent Systems, IRCON and more

Stocks to watch out for today: IRCON International, Maruti Suzuki, Infosys, HCL Tech, RITES, Paytm, Persistent Systems, IDBI Bank, Glenmark Pharmaceuticals, HDFC Asset Management Company, Sun Pharma, Advance Lifestyles and more

Glenmark arm inks licensing pact with Astria Therapeutics - Vimarsana News

Glenmark arm inks licensing pact with Astria Therapeutics

With the execution of this agreement, Ichnos has successfully licensed its two assets for inflammatory and immunological diseases, a key milestone in the company's prioritisation of its pipeline of oncology drug candidates, Ichnos Sciences said in a statement filed on BSE by Glenmark.